NURS 6521N Advanced Pharmacology Midterm Exam Prep
Document | 2026/2027 Edition | 250 Verified Questions
NURS 6521N Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation guide is designed for graduate nursing students
enrolled in NURS 6521N Advanced Pharmacology. It features 250 verified questions and answers that
reflect the latest curriculum and clinical practice guidelines. Each question is accompanied by detailed
rationales and distractor explanations to enhance understanding of pharmacokinetics,
pharmacodynamics, and therapeutic decision-making. Ideal for advanced practice nursing students
seeking a high-yield, evidence-based review for the 2026/2027 academic year.
Abstract:
This document provides a rigorous review of advanced pharmacology concepts essential for graduate nursing
students preparing for the NURS 6521N midterm examination. The 250 verified questions are organized by content
area, including pharmacokinetics, autonomic nervous system drugs, cardiovascular agents, antimicrobials, and
endocrine pharmacotherapy. Each question includes a detailed rationale explaining the correct answer and why
distractors are incorrect, promoting deeper learning. Special emphasis is placed on clinical application, safe
prescribing practices, and patient-centered care. The content aligns with the 2026/2027 academic year
competencies and reflects current evidence-based guidelines from major medical associations. This resource is
curated to help advanced practice nursing students achieve mastery and excel in their midterm assessment.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics & 1-50 Absorption, distribution, metabolism, 20%
Pharmacodynamics excretion; receptor theory; dose-response
relationships; therapeutic index
Autonomic Nervous System 51-90 Cholinergic agonists/antagonists; adrenergic 16%
Drugs agonists/antagonists; ganglionic blockers;
neuromuscular blockers
Cardiovascular Pharmacology 91-140 Antihypertensives, antiarrhythmics, heart 20%
failure drugs, anticoagulants, antiplatelets,
lipid-lowering agents
Antimicrobial Therapy 141-180 Antibiotics, antivirals, antifungals, 16%
resistance mechanisms, stewardship
principles
Endocrine & Metabolic 181-210 Insulin, oral hypoglycemics, thyroid 12%
Pharmacology hormones, osteoporosis drugs, weight
management agents
Special Populations & 211-250 Pediatric and geriatric dosing, pregnancy 16%
Toxicology and lactation, drug interactions overdose
management
Page 1
,Q1. A patient with decreased hepatic blood flow due to congestive heart failure is started on a drug
that undergoes extensive first-pass metabolism. How will the pharmacokinetics of this drug most
likely be altered?
A. Increased volume of distribution
B. Decreased bioavailability
C. Increased elimination half-life
D. Increased plasma protein binding
Correct Answer: C. Increased elimination half-life
Rationale: Reduced hepatic blood flow diminishes clearance of high-extraction drugs, prolonging
elimination half-life. Bioavailability may actually increase due to reduced first-pass effect. Volume of
distribution and protein binding are not directly affected by blood flow.
Why Wrong:
A - Volume of distribution is primarily determined by drug lipophilicity and protein binding, not
hepatic blood flow.
B - Decreased first-pass metabolism leads to increased, not decreased, bioavailability.
D - Protein binding is affected by albumin levels and drug affinity, not hepatic blood flow.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4
Q2. Two agonists, Drug X and Drug Y, bind to the same receptor. Drug X produces a maximal
response at 10 mg, while Drug Y requires 50 mg to achieve the same maximal response. Which
statement accurately describes these drugs?
A. Drug X has higher efficacy than Drug Y.
B. Drug Y has lower potency than Drug X.
C. Drug Y is a partial agonist.
D. Drug X has lower affinity for the receptor.
Correct Answer: B. Drug Y has lower potency than Drug X.
Rationale: Potency refers to the dose required to produce a given effect; Drug Y requires a higher dose,
so it is less potent. Both achieve the same maximal response, indicating equal efficacy. Affinity cannot be
determined without binding studies. Both are full agonists.
Why Wrong:
A - Efficacy is the maximal effect; both achieve the same maximum, so efficacy is equal.
C - Partial agonists produce lower maximal response than full agonists; here both reach the same
maximum.
D - The lower dose of Drug X could imply higher affinity, but this is not directly measured from
dose-response curves; potency depends on affinity and efficacy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 1
Page 2
,Q3. A patient with a penicillin allergy requires treatment for a serious Gram-negative infection
caused by a -lactamase-producing organism. Which of the following agents would be most
appropriate?
A. Amoxicillin
B. Cefazolin
C. Aztreonam
D. Imipenem-cilastatin
Correct Answer: C. Aztreonam
Rationale: Aztreonam is a monobactam with activity against Gram-negative aerobes and is generally safe
in penicillin-allergic patients because cross-reactivity is minimal. Amoxicillin and imipenem are
contraindicated. Cefazolin has cross-sensitivity risk and poor -lactamase stability.
Why Wrong:
A - Amoxicillin is a penicillin; contraindicated in penicillin allergy and often ineffective against
-lactamase producers.
B - Cefazolin has cross-reactivity risk in type I allergies and is not reliably active against
-lactamase-producing organisms.
D - Imipenem-cilastatin is a carbapenem; cross-reactivity is high, and it is contraindicated.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 77
Q4. A patient with hypertension and type 2 diabetes mellitus has microalbuminuria. Which
antihypertensive class is preferred to delay progression of nephropathy?
A. Thiazide diuretics
B. Beta blockers
C. Angiotensin-converting enzyme inhibitors
D. Calcium channel blockers
Correct Answer: C. Angiotensin-converting enzyme inhibitors
Rationale: ACE inhibitors reduce intraglomerular pressure by dilating efferent arterioles, providing
renoprotective effects beyond blood pressure reduction. They are first-line for diabetic nephropathy with
microalbuminuria. Thiazides and beta blockers lack this specific benefit. CCBs are less effective at
reducing proteinuria.
Why Wrong:
A - Thiazides are effective for hypertension but do not directly reduce proteinuria or slow
nephropathy progression.
B - Beta blockers reduce blood pressure but do not offer specific renoprotection.
D - Calcium channel blockers, especially dihydropyridines, may worsen proteinuria in some studies.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 43
Page 3
, Q5. A patient is prescribed an opioid agonist that produces analgesia primarily through mu
receptor activation but also has significant kappa receptor activity. Which effect is most likely to be
associated with the kappa activation?
A. Euphoria
B. Respiratory depression
C. Dysphoria
D. Physical dependence
Correct Answer: C. Dysphoria
Rationale: Kappa receptor activation is associated with dysphoria, sedation, and psychotomimetic
effects, in contrast to mu activation which produces euphoria. Respiratory depression and physical
dependence are primarily mu-mediated.
Why Wrong:
A - Euphoria is mediated mainly by mu receptors.
B - Respiratory depression is a mu-, not kappa-, mediated effect.
D - Physical dependence is largely due to mu receptor chronic activation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 14
Q6. Which statement about the pharmacodynamics of sulfonylureas is correct?
A. They increase insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta
cells.
B. They increase peripheral glucose uptake by activating PPAR-gamma receptors.
C. They delay carbohydrate absorption in the gastrointestinal tract.
D. They inhibit hepatic gluconeogenesis primarily.
Correct Answer: A. They increase insulin secretion by closing ATP-sensitive potassium channels in
pancreatic beta cells.
Rationale: Sulfonylureas bind to SUR1 subunits on pancreatic beta cells, closing KATP channels, which
depolarizes the cell and triggers insulin release. Options B (thiazolidinediones), C (alpha-glucosidase
inhibitors), and D (metformin) describe other drug classes.
Why Wrong:
B - Activating PPAR-gamma receptors is the action of thiazolidinediones, not sulfonylureas.
C - Delaying carbohydrate absorption is the mechanism of alpha-glucosidase inhibitors.
D - Inhibiting hepatic gluconeogenesis is a primary effect of metformin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 80
Page 4
Document | 2026/2027 Edition | 250 Verified Questions
NURS 6521N Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation guide is designed for graduate nursing students
enrolled in NURS 6521N Advanced Pharmacology. It features 250 verified questions and answers that
reflect the latest curriculum and clinical practice guidelines. Each question is accompanied by detailed
rationales and distractor explanations to enhance understanding of pharmacokinetics,
pharmacodynamics, and therapeutic decision-making. Ideal for advanced practice nursing students
seeking a high-yield, evidence-based review for the 2026/2027 academic year.
Abstract:
This document provides a rigorous review of advanced pharmacology concepts essential for graduate nursing
students preparing for the NURS 6521N midterm examination. The 250 verified questions are organized by content
area, including pharmacokinetics, autonomic nervous system drugs, cardiovascular agents, antimicrobials, and
endocrine pharmacotherapy. Each question includes a detailed rationale explaining the correct answer and why
distractors are incorrect, promoting deeper learning. Special emphasis is placed on clinical application, safe
prescribing practices, and patient-centered care. The content aligns with the 2026/2027 academic year
competencies and reflects current evidence-based guidelines from major medical associations. This resource is
curated to help advanced practice nursing students achieve mastery and excel in their midterm assessment.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics & 1-50 Absorption, distribution, metabolism, 20%
Pharmacodynamics excretion; receptor theory; dose-response
relationships; therapeutic index
Autonomic Nervous System 51-90 Cholinergic agonists/antagonists; adrenergic 16%
Drugs agonists/antagonists; ganglionic blockers;
neuromuscular blockers
Cardiovascular Pharmacology 91-140 Antihypertensives, antiarrhythmics, heart 20%
failure drugs, anticoagulants, antiplatelets,
lipid-lowering agents
Antimicrobial Therapy 141-180 Antibiotics, antivirals, antifungals, 16%
resistance mechanisms, stewardship
principles
Endocrine & Metabolic 181-210 Insulin, oral hypoglycemics, thyroid 12%
Pharmacology hormones, osteoporosis drugs, weight
management agents
Special Populations & 211-250 Pediatric and geriatric dosing, pregnancy 16%
Toxicology and lactation, drug interactions overdose
management
Page 1
,Q1. A patient with decreased hepatic blood flow due to congestive heart failure is started on a drug
that undergoes extensive first-pass metabolism. How will the pharmacokinetics of this drug most
likely be altered?
A. Increased volume of distribution
B. Decreased bioavailability
C. Increased elimination half-life
D. Increased plasma protein binding
Correct Answer: C. Increased elimination half-life
Rationale: Reduced hepatic blood flow diminishes clearance of high-extraction drugs, prolonging
elimination half-life. Bioavailability may actually increase due to reduced first-pass effect. Volume of
distribution and protein binding are not directly affected by blood flow.
Why Wrong:
A - Volume of distribution is primarily determined by drug lipophilicity and protein binding, not
hepatic blood flow.
B - Decreased first-pass metabolism leads to increased, not decreased, bioavailability.
D - Protein binding is affected by albumin levels and drug affinity, not hepatic blood flow.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4
Q2. Two agonists, Drug X and Drug Y, bind to the same receptor. Drug X produces a maximal
response at 10 mg, while Drug Y requires 50 mg to achieve the same maximal response. Which
statement accurately describes these drugs?
A. Drug X has higher efficacy than Drug Y.
B. Drug Y has lower potency than Drug X.
C. Drug Y is a partial agonist.
D. Drug X has lower affinity for the receptor.
Correct Answer: B. Drug Y has lower potency than Drug X.
Rationale: Potency refers to the dose required to produce a given effect; Drug Y requires a higher dose,
so it is less potent. Both achieve the same maximal response, indicating equal efficacy. Affinity cannot be
determined without binding studies. Both are full agonists.
Why Wrong:
A - Efficacy is the maximal effect; both achieve the same maximum, so efficacy is equal.
C - Partial agonists produce lower maximal response than full agonists; here both reach the same
maximum.
D - The lower dose of Drug X could imply higher affinity, but this is not directly measured from
dose-response curves; potency depends on affinity and efficacy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 1
Page 2
,Q3. A patient with a penicillin allergy requires treatment for a serious Gram-negative infection
caused by a -lactamase-producing organism. Which of the following agents would be most
appropriate?
A. Amoxicillin
B. Cefazolin
C. Aztreonam
D. Imipenem-cilastatin
Correct Answer: C. Aztreonam
Rationale: Aztreonam is a monobactam with activity against Gram-negative aerobes and is generally safe
in penicillin-allergic patients because cross-reactivity is minimal. Amoxicillin and imipenem are
contraindicated. Cefazolin has cross-sensitivity risk and poor -lactamase stability.
Why Wrong:
A - Amoxicillin is a penicillin; contraindicated in penicillin allergy and often ineffective against
-lactamase producers.
B - Cefazolin has cross-reactivity risk in type I allergies and is not reliably active against
-lactamase-producing organisms.
D - Imipenem-cilastatin is a carbapenem; cross-reactivity is high, and it is contraindicated.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 77
Q4. A patient with hypertension and type 2 diabetes mellitus has microalbuminuria. Which
antihypertensive class is preferred to delay progression of nephropathy?
A. Thiazide diuretics
B. Beta blockers
C. Angiotensin-converting enzyme inhibitors
D. Calcium channel blockers
Correct Answer: C. Angiotensin-converting enzyme inhibitors
Rationale: ACE inhibitors reduce intraglomerular pressure by dilating efferent arterioles, providing
renoprotective effects beyond blood pressure reduction. They are first-line for diabetic nephropathy with
microalbuminuria. Thiazides and beta blockers lack this specific benefit. CCBs are less effective at
reducing proteinuria.
Why Wrong:
A - Thiazides are effective for hypertension but do not directly reduce proteinuria or slow
nephropathy progression.
B - Beta blockers reduce blood pressure but do not offer specific renoprotection.
D - Calcium channel blockers, especially dihydropyridines, may worsen proteinuria in some studies.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 43
Page 3
, Q5. A patient is prescribed an opioid agonist that produces analgesia primarily through mu
receptor activation but also has significant kappa receptor activity. Which effect is most likely to be
associated with the kappa activation?
A. Euphoria
B. Respiratory depression
C. Dysphoria
D. Physical dependence
Correct Answer: C. Dysphoria
Rationale: Kappa receptor activation is associated with dysphoria, sedation, and psychotomimetic
effects, in contrast to mu activation which produces euphoria. Respiratory depression and physical
dependence are primarily mu-mediated.
Why Wrong:
A - Euphoria is mediated mainly by mu receptors.
B - Respiratory depression is a mu-, not kappa-, mediated effect.
D - Physical dependence is largely due to mu receptor chronic activation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 14
Q6. Which statement about the pharmacodynamics of sulfonylureas is correct?
A. They increase insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta
cells.
B. They increase peripheral glucose uptake by activating PPAR-gamma receptors.
C. They delay carbohydrate absorption in the gastrointestinal tract.
D. They inhibit hepatic gluconeogenesis primarily.
Correct Answer: A. They increase insulin secretion by closing ATP-sensitive potassium channels in
pancreatic beta cells.
Rationale: Sulfonylureas bind to SUR1 subunits on pancreatic beta cells, closing KATP channels, which
depolarizes the cell and triggers insulin release. Options B (thiazolidinediones), C (alpha-glucosidase
inhibitors), and D (metformin) describe other drug classes.
Why Wrong:
B - Activating PPAR-gamma receptors is the action of thiazolidinediones, not sulfonylureas.
C - Delaying carbohydrate absorption is the mechanism of alpha-glucosidase inhibitors.
D - Inhibiting hepatic gluconeogenesis is a primary effect of metformin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 80
Page 4
